RPRX logo

Royalty Pharma (RPRX)

Profile

Full Name

Royalty Pharma plc

Ticker Symbol

RPRX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

June 16, 2020

Indexes

Not included

Website

http://www.royaltypharma.com

Employees

75

Key Details

Price

$30.76

Market Cap

Last Dividend

$0.22

TTM Dividend Yield

2.76%

Annual Revenue

$2.26B(-3.86% YoY)

Annual EPS

$1.91(-24.51% YoY)

PE Ratio

17.06

Next earnings date

May 9, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$30.76
RPRX price is $30.76

Price All-time High

$52.82
RPRX price is currently -41.76% below its historical high of $52.82

Price Today Change

-3.72%
RPRX price is down -3.72% today

Price YTD Change

+20.58%
RPRX price is up +20.58% since January 1st

Price 1-year Change

+3.38%
RPRX price is up +3.38% year-on-year

Price 3-year Change

-21.05%
RPRX price is down -21.05% over the past 3 years

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market Cap

$13.33B
RPRX market capitalization is $13.33 billion

Market Cap 3-year Change

-21.41%
RPRX market capitalization is down -21.41% over the past 3 years

Market Cap All-time High

$20.50B
RPRX market capitalization is currently -34.98% below its historical high of $20.50 billion

Market Cap Sector Rank

94.13%
RPRX market capitalization is higher than 94.13% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

-2.99%
RPRX shares outstanding is down -2.99% year-on-year

Shares Outstanding 3-Year Change

+0.08%
RPRX shares outstanding is up +0.08% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.07
RPRX beta is 0.07

200-day SMA

$28.45
RPRX price is currently +8.13% above its 200-day simple moving average

50-day SMA

$32.42
RPRX price is currently -5.11% below its 50-day simple moving average

RSI

35.45
RPRX 14-day relative strength index is 35.45

Volume

1.34
RPRX 30-day relative volume is 1.34

ATR

$0.78
RPRX average true range is $0.78

10-day Historical Volatility

35.14%
RPRX 10-day historical volatility is 35.14%

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Last Paid Dividend

$0.22
RPRX last dividend was $0.22 per share, with an ex-dividend date of February 21, 2025

Next Dividend

-
RPRX next dividend has not yet been announced

Dividend per share

Dividend Per Share

$0.84
RPRX annual dividend per share is $0.84

Dividend per share Sector Rank

36.47%
RPRX annual dividend per share is higher than 36.47% of companies in Healthcare sector

Dividend per share 1-Year Change

+5%
RPRX annual dividend per share is up +5% year-on-year

Dividend per share 3-Year Change

+23.53%
RPRX annual dividend per share is up +23.53% over the past 3 years

Dividend yield

Dividend Yield

2.73%
RPRX annual dividend yield is 2.73%

Dividend yield Sector Rank

60.71%
RPRX annual dividend yield is higher than 60.71% of companies in Healthcare sector

Other

Payout Ratio

43.83%
RPRX annual payout ratio is 43.83%

Dividends Paid

$376.46M
RPRX annual dividends paid is $376.46 million

Free Cash Flow

$2.77B
RPRX annual free cash flow is $2.77 billion

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$2.26B
RPRX annual revenue is $2.26 billion

Revenue Analysts Estimate

$2.95B
RPRX annual revenue is currently -23.16% lower than the consensus analysts' forecast

Revenue 1-year Change

-3.86%
RPRX annual revenue is down -3.86% year-on-year

Revenue Sector Rank

85.86%
RPRX annual revenue is higher than 85.86% of companies in Healthcare sector

EPS

EPS

$1.91
RPRX annual earnings per share is $1.91

EPS Analysts Estimate

$4.67
RPRX annual earnings per share is currently -59.11% lower than the consensus analysts' forecast

EPS 1-year Change

-24.51%
RPRX annual earnings per share is down -24.51% year-on-year

EPS Sector Rank

91.87%
RPRX annual earnings per share is higher than 91.87% of companies in Healthcare sector

Profit

Gross Profit

-
RPRX annual gross profit value is unknown

Gross Margin

-
RPRX annual gross profit margin value is unknown

Operating Profit

$1.29B
RPRX annual operating income is $1.29 billion

Operating Margin

57.10%
RPRX annual operating profit margin is 57.10%

Net Income

$858.98M
RPRX annual net profit is $858.98 million

Net Margin

37.95%
RPRX annual net profit margin is 37.95%

Expenses

Total Expenses

$971.13M
RPRX annual total expenses is $971.13 million

Operating Expenses

$971.13M
RPRX annual total operating expenses is $971.13 million

Cost Of Goods Sold

-
RPRX annual cost of goods sold value is unknown

Selling, General & Administrative Expenses

$236.67M
RPRX annual SGA is $236.67 million

Depreciation And Amortization

$0.00
RPRX annual depreciation & amortization is $0.00

Interest Expense

$225.51M
RPRX annual interest expense is $225.51 million

Income Tax

$0.00
RPRX annual income tax is $0.00

EBIT & EBITDA

EBIT

$1.56B
RPRX annual earnings before interest & taxes is $1.56 billion

EBITDA

$1.56B
RPRX annual EBITDA is $1.56 billion

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total Assets

$18.22B
RPRX annual total assets is $18.22 billion

Non Current Assets

$16.42B
RPRX annual long term assets is $16.42 billion

Current Assets

$1.80B
RPRX annual total current assets is $1.80 billion

Cash And Cash Equivalents

$929.03M
RPRX annual cash & cash equivalents is $929.03 million

Accounts Receivable

-
RPRX annual accounts receivable value is unknown

Inventory

-
RPRX annual inventory value is unknown

Liabilities

Total Liabilities

$7.88B
RPRX annual total liabilities is $7.88 billion

Long Term Liabilities

$6.63B
RPRX annual total long term liabilities is $6.63 billion

Current Liabilities

$1.25B
RPRX annual total current liabilities is $1.25 billion

Accounts Payable

$13.37M
RPRX annual accounts payable is $13.37 million

Debt

Total Debt

$7.61B
RPRX annual total debt is $7.61 billion

Total Debt 1-year Change

+24.08%
RPRX annual total debt is up +24.08% year-on-year

Long Term Debt

$6.61B
RPRX annual long term debt is $6.61 billion

Short Term Debt

$997.77M
RPRX annual short term debt is $997.77 million

Equity & Capital

Shareholders Equity

$6.95B
RPRX annual stockholders equity is $6.95 billion

Book Value

$6.95B
RPRX annual book value is $6.95 billion

Retained Earnings

$2.85B
RPRX annual retained earnings is $2.85 billion

Working Capital

$548.52M
RPRX annual working capital is $548.52 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash From Operations

$2.77B
RPRX annual cash flow from operations is $2.77 billion

Cash From Operations 1-year Change

-7.32%
RPRX annual cash flow from operations is down -7.32% year-on-year

Cash From Investing

-$2.68B
RPRX annual cash flow from investing activities is -$2.68 billion

Cash From Investing 1-year Change

-29.2%
RPRX annual cash flow from investing activities is down -29.2% year-on-year

Cash From Financing

$361.14M
RPRX annual cash flow from financing activities is $361.14 million

Cash From Financing 1-year Change

+116.81%
RPRX annual cash flow from financing activities is up +116.81% year-on-year

CAPEX

CAPEX

-
RPRX annual capital expenditures value is unknown

CAPEX 1-year Change

-
RPRX annual capital expenditures 1-year change is unknown

Free Cash Flow

Free Cash Flow

$2.77B
RPRX annual free cash flow is $2.77 billion

Free Cash Flow 1-year Change

-7.32%
RPRX annual free cash flow is down -7.32% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross Margin

-
RPRX annual gross profit margin value is unknown

Operating Margin

57.10%
RPRX annual operating profit margin is 57.10%

Net Margin

37.95%
RPRX annual net profit margin is 37.95%

ROA & ROE

ROA

4.96%
RPRX annual return on assets is 4.96%

ROE

8.41%
RPRX annual return on equity is 8.41%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

17.06
RPRX price to earnings ratio is 17.06

PE Ratio Sector Rank

27.67%
RPRX price to earnings ratio is higher than 27.67% of companies in Healthcare sector

PB Ratio

PB Ratio

1.92
RPRX price to book ratio is 1.92

PB Ratio Sector Rank

61.12%
RPRX price to book ratio is higher than 61.12% of companies in Healthcare sector

PS Ratio

PS Ratio

5.89
RPRX price to sales ratio is 5.89

PS Ratio Sector Rank

68.7%
RPRX price to sales ratio is higher than 68.7% of companies in Healthcare sector

Enterprise value

Enterprise Value

$20.01B
RPRX enterprise value is $20.01 billion

Enterprise Value Sector Rank

94.78%
RPRX enterprise value is higher than 94.78% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

12.86
RPRX EV/EBITDA is 12.86

EV/EBITDA Sector Rank

85.31%
RPRX EV/EBITDA is higher than 85.31% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current Ratio

1.44
RPRX annual current ratio is 1.44

Quick Ratio

-
RPRX annual quick ratio value is unknown

Leverage

Debt To Equity

1.10
RPRX annual debt to equity ratio is 1.10

Interest Coverage Ratio

6.90
RPRX annual interest coverage ratio is 6.90

Risk & Stability

Piotroski F-Score

-
RPRX piotroski f-score value is unknown

Altman Z-Score

1.68
RPRX altman z-score is 1.68

Analyst ratings

Recent major analysts updates

Oct 25, 24 Citigroup
Buy
Aug 14, 24 Goldman Sachs
Buy
Jul 11, 24 Morgan Stanley
Overweight
Jun 3, 24 UBS
Neutral
Apr 12, 24 B of A Securities
Buy
Feb 20, 24 JP Morgan
Overweight
Feb 20, 24 Goldman Sachs
Buy
Nov 9, 23 Morgan Stanley
Overweight
Oct 11, 23 Morgan Stanley
Overweight
Aug 9, 23 Morgan Stanley
Overweight

Institutional Ownership

Similar stocks

UTHR logo
United Therapeutics (UTHR)
ITCI logo
Intra-Cellular Therapies (ITCI)
BMRN logo
BioMarin Pharmaceutical (BMRN)
HOLX logo
Hologic (HOLX)
INSM logo
Insmed Incorporated (INSM)
FMS logo
Fresenius Medical Care AG & Co KGaA (FMS)
ICLR logo
ICON Public Limited (ICLR)
SMMT logo
Summit Therapeutics (SMMT)
SOLV logo
Solventum (SOLV)
  • What is the ticker symbol for Royalty Pharma?
  • Does Royalty Pharma pay dividends?
  • What sector is Royalty Pharma in?
  • What industry is Royalty Pharma in?
  • What country is Royalty Pharma based in?
  • When did Royalty Pharma go public?
  • Is Royalty Pharma in the S&P 500?
  • Is Royalty Pharma in the NASDAQ 100?
  • Is Royalty Pharma in the Dow Jones?
  • When was Royalty Pharma's last earnings report?
  • When does Royalty Pharma report earnings?
  • Should I buy Royalty Pharma stock now?

What is the ticker symbol for Royalty Pharma?

The ticker symbol for Royalty Pharma is NASDAQ:RPRX

Does Royalty Pharma pay dividends?

Yes, Royalty Pharma pays dividends. The last payment was $0.22, with an ex-dividend date on February 21, 2025

What sector is Royalty Pharma in?

Royalty Pharma is in the Healthcare sector

What industry is Royalty Pharma in?

Royalty Pharma is in the Biotechnology industry

What country is Royalty Pharma based in?

Royalty Pharma is headquartered in United States

When did Royalty Pharma go public?

Royalty Pharma's initial public offering (IPO) was on June 16, 2020

Is Royalty Pharma in the S&P 500?

No, Royalty Pharma is not included in the S&P 500 index

Is Royalty Pharma in the NASDAQ 100?

No, Royalty Pharma is not included in the NASDAQ 100 index

Is Royalty Pharma in the Dow Jones?

No, Royalty Pharma is not included in the Dow Jones index

When was Royalty Pharma's last earnings report?

Royalty Pharma's most recent earnings report was on Feb 11, 2025

When does Royalty Pharma report earnings?

The next expected earnings date for Royalty Pharma is May 9, 2025

Should I buy Royalty Pharma stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page